Current scenario of indole-azole hybrids with anticancer potential: part II. Imidazole, oxadiazole, oxazole, and isoxazole hybrids.

Indole derivatives have emerged as a "privileged pharmacophore" in cancer therapy, owing to their inherent structural flexibility, low intrinsic toxicity, and high binding affinity for oncogenic targets. Indole moiety readily accommodates functional group modifications or modular assembly with other bioactive moieties, allowing the integration of distinct functional modules onto the indole scaffold to achieve tailored biological effects. The structural versatility of indole derivatives allows them to target a broad spectrum of cancer types and tackle pivotal therapeutic challenges in oncology, such as multidrug resistance and tumor heterogeneity. Indole-azole hybrids represent a versatile class of anticancer agents that harness the synergistic potential of two privileged pharmacophores, the indole core and azole moiety. Their inherent multi-targeted modes of action and structural flexibility further render them promising candidates for advancing personalized cancer therapy, with considerable utility in treating hard-to-treat cancer subtypes. This review summarizes recent advances in indole-imidazole/oxadiazole/oxazole/isoxazole hybrids with anticancer potential, covering articles published from 2021 to the present. To delineate the key molecular features that govern the anticancer potency of these hybrids, this review further presents a detailed structure-activity relationships (SARs) analysis and conducts an in-depth exploration of their underlying mechanisms of action.